Half of the patients who were hospitalized for Covid-19 a year ago have some symptoms today, according to a study in the scientific journal ‘The Lancet’. In other news, Brazil will begin to produce the vaccine created between the Pfizer / BioNTech laboratories for distribution in Latin America and the New Zealand Government is working to combat the new outbreak of the virus with the strict quarantine, imposed last week.
The world continues to fight Covid-19 more than a year after the WHO declared the health emergency a pandemic.
Almost a year and a half after the first case, various vaccines have been approved around the planet and now the Executives are trying to reach the maximum population to stop the advance and spread of new variants of the virus.
With the echoes of quarantines coming true in countries like New Zealand and Australia, the world adds 214.9 million cases since the start of the pandemic and more than 4.4 million deaths due to the virus.
According to Johns Hopkins University, 5.1 million doses of the Covid-19 vaccine have been administered worldwide. And while higher-income countries plan a third booster dose, other nations have been unable to inoculate a significant portion of their population.
- Half of those hospitalized by Covid-19 maintain some symptoms a year later
A study conducted by the British medical journal ‘The Lancet’ yields worrying results: a year after being hospitalized for Covid-19, patients still suffer from symptoms that could last even longer.
The study was conducted at a Wuhan hospital, where researchers examined 1,276 patients six and 12 months after being discharged from Jin Yin-tan Hospital between January and May 2020. The results showed that despite Most of the symptoms disappeared, at least one persisted in almost half – 49% – of the cases after a year.
“Although most recovered, health problems persisted in some patients, especially in those who were critical during their hospitalization,” said Bin Cao, a researcher at the National Center for Respiratory Medicine of China through a statement from the journal ‘ The Lancet ‘.
Among the persistent symptoms, the medical institution recorded fatigue or muscle weakness, while one in three patients suffered from breathing difficulties. In general, those patients with an average of 57 years hospitalized have a poorer health than those who have not faced the virus.
Of the 594 who were not retired before contracting the disease, 88% had returned to their original job one year after being discharged and 76% assured that they returned to work at the same level as before entering the hospital.
The study reflects that there are not only physical ailments, but there are also psychological impacts such as confusion, others such as shortness of breath, anxiety or depression. Quite a challenge for researchers, since these symptoms are largely subjective and change depending on the patient.
- Brazil will produce and distribute the Pfizer / BioNTech vaccine in Latin America
The Brazilian multinational Eurofarma will begin to produce and distribute the inoculant manufactured by the consortium of the Pfizer / BioNTech laboratories. The news came on Thursday, when the Brazilian pharmaceutical company announced the agreement to produce the vaccines – and distribute them – throughout Latin America.
“Eurofarma will carry out manufacturing activities within the supply chain and the global Covid-19 vaccine production network that Pfizer and BioNTech have, which now span four continents and will include 20 manufacturing units,” the Brazilian pharmaceutical company reported. it’s a statement.
Preparations are expected to begin “immediately” to be able to make regional shipments from 2022. In this regard, Pfizer President Albert Bourla stressed that “everyone, regardless of financial condition, ethnicity, religion or geography, deserves access to the life-saving vaccines. ” So far, the Pfizer / BioNTech solution has been in short supply in Latin American nations.
The agreement comes after the decision of the Brazilian Ministry of Health to apply a booster dose to vulnerable people and those over 70 years of age, six months after completing the vaccination regimen. A reminder that the Health portfolio has said it prefers to be from the Pfizer / BioNTech vaccine.
This vaccine is used in 120 countries and Brazil was the first to grant it definitive registration by the National Health Surveillance Agency, even earlier than in the United States.
- New Zealand tries to slow down the Covid-19 case curve
The Delta variant of the coronavirus has put New Zealand’s “zero contagion” strategy to the test, achieved so far through strict lockdowns at times when there was no significant rebound in the virus.
Prime Minister Jacinda Ardern announced this Friday that as of September 1, the confinement that the country has been facing since last week will be relaxed, after which the effectiveness of this against the Delta variant, the most contagious registered to date, will be seen. the moment.
Along with the announcement, the leader also said that the alarm level was lowered from four to three in the country, something that allows the reopening of some businesses and meetings – such as weddings and other events – with up to ten people.
This opening will apply throughout the country except in the most populous city, Auckland, where the outbreak with a local contagion of Covid-19 was registered and in the neighboring area of Northland.
Since the pandemic began, New Zealand has only recorded 26 deaths from the virus in a population of 5 million. Furthermore, the per capita death rate is about 400 times lower than in countries like the United Kingdom and the United States.
As an exception globally, the life expectancy of New Zealanders increased in 2020 as measures against the virus helped reduce other seasonal ailments such as the flu.
However, the country receives criticism because, despite its effective management of the pandemic, which consisted of closing its borders and carrying out hard and early confinements, it has one of the slowest vaccination campaigns of developed nations, with only 20 % of the population with the complete guideline.
With EFE and Reuters